Compare Cronos Group Inc (CRON) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Sony Group Corp — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Sony Group Corp trades at $24.09 (market cap $138.06B). The key difference: Sony Group Corp is far larger — about 115× Cronos Group Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Sony Group Corp for 96 Days on average.
| CRON | SONY | |
|---|---|---|
Market Cap | $1.20B | $138.06B |
Volume | 450,387 | 3,986,731 |
Sector | Health | Technology |
52-Week High | $3.55 | $30.26 |
52-Week Low | $2.30 | $19.32 |
Typical Hold Time | 22 Days | 96 Days |
Enterprise Value | $401.73M | $135.96B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
Sony trades at $23.95, up 0.42% with neutral technical signals. The company shows strong cash flow generation ($2.32T operating cash flow in 2025) and beat earnings expectations in two of the last three quarters. However, 2026 projections indicate potential challenges with negative net income margin and declining revenue. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations among 16 analysts covering the stock.
Sony presents a mixed investment case with solid entertainment assets and cash flow strength offset by near-term profitability concerns. The stock's reasonable valuation (P/E 19.93, P/S 1.75) and strong analyst support provide upside potential, but investors must monitor execution against 2026 guidance and competitive pressures in entertainment markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
